Defining the Role for ZBP-89 in ATM-mediated DNA Damage Response to Irradiation in the Intestine

ZBP-89 (ZNF148, Zfp148) is a zinc-finger transcription factor that inhibits cellular proliferation when overexpressed in cell lines. ZBP-89 forms a protein-protein interaction with p53 and Ataxia-telangiectasia mutated (ATM). However, it is unclear how the interaction modulates the function of these two proteins in vivo. Double strand DNA breakage induced by -irradiation induces ATM phosphoinositol kinase activity, which initiates a cascade of events culminating in cell cycle arrest, DNA repair or apoptosis. Elevated levels of ZBP-89 induce growth arrest and apoptosis in gastrointestinal cell lines. Therefore, we hypothesize that ZBP-89 facilitates cell growth arrest and activation of the DNA repair pathway after ATM activation. To test this hypothesis, we irradiated 4 groups of mice—1) C57BL/6 mice without any genetic deletion; 2) mice with one or both copies of ATM deleted from the intestinal mucosa; 3) mice with the ATM deletion and one copy of Zfp148 deleted; 4) ATM deletion with both copies of Zfp148 deleted. After the intestines were fixed, paraffin-embedded and sectioned, I performed the de-paraffinization step for immunohistochemistry of ZBP-89, p53 and H2AX. To stain for ZBP-89 protein, I performed an antigen retrieval step using sodium citrate, followed by blocking with 3% hydrogen peroxide and serum. I then added the primary antibody then the secondary antibodies. I used diaminobenzidine (DAB), a chromogenic detection method to visualize the antigen-antibody complex. I then counterstained with hematoxylin. We predict that the mice with a deletion of ZBP-89 will exhibit more tissue damage as a result of the irradiation and DNA damage. Results are pending

The imperative to invest in science has never been greater

In order to sustain and improve the health of Americans, to ensure our ability to overcome new health challenges, and to realize the economic benefits of a vigorous scientific economy, we encourage our government to implement three actions. First, establish predictable, managed growth in the US scientific enterprise by establishing a sustainable and predictable real annual increase in science funding. This will require additional investments in the proven NIH-university partnership to maintain our world-leading position in biomedical science. Second, preserve the current cadre of well-trained junior scientists, including physician-scientists, and maintain a pipeline of young scientists motivated to innovate and improve health. Third, analyze changing health needs and priorities for health science–related investments in order to address ongoing shifts in population demographics and diseases, opportunities for improved prevention or treatment, and the availability of new scientific tools and disciplines. It is in the nation’s best interests -- for good health, for a robust economy, and for scientific leadership -- to advocate for strong federal support of biomedical science in America’s great research universities. Translation of this science yields enormous benefits to our nation’s health and to the economy